Luminespib (Synonyms: VER-52296; AUY922; NVP-AUY922)

目录号: HY-10215 纯度: 99.74%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Luminespib (VER-52296) 是有效的 HSP90 抑制剂，抑制 HSP90α 和 HSP90β 的 IC₅₀ 分别为 7.8 和 21 nM。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

Luminespib Chemical Structure

CAS No. : 747412-49-3

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥550	In-stock
1 mg	￥250	In-stock
5 mg	￥498	In-stock
10 mg	￥700	In-stock
25 mg	￥1500	In-stock
50 mg	￥2250	In-stock
100 mg	￥3500	In-stock
200 mg	￥5338	In-stock
500 mg		询价
1 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

MCE 顾客使用本产品发表的 18 篇科研文献

Proliferation Assay

: Luminespib purchased from MCE. Usage Cited in: Blood. 2018 Jul 19;132(3):307-320. [Abstract]; K562, KCL22 and HL60 are treated with the indicated (cytotoxic) concentration of Amidopyrine (AX) and AUY922 for 48h and later protein lysates are subjected to immunoblot analysis.

: Luminespib purchased from MCE. Usage Cited in: Clin Cancer Res. 2018 Feb 15;24(4):794-806. [Abstract]; HSP90 inhibition with Luminespib or Ganetespib treatment at 50 and 100 nM for 24 hours in three CMS4 cell lines with response to HSP90 inhibition (CACO2, LIM2099 and SW480) confirmed up-regulation of HSP70 and HSP40 at the protein level in treated versus untreated control cells (western blotting).

: Luminespib purchased from MCE. Usage Cited in: Stem Cell Res. 2014 Sep;13(2):284-99. [Abstract]; HSP90 inhibition affects ciliation. 24 h treatment with 100 nM AUY922 significantly affects ciliation, under 20% (left) O₂ tension but not 5% O₂ tension (right).

Luminespib 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 HSP 亚型特异性产品:

查看所有亚型

HSP40 HSP70 HSP90 HSP105 HSF1 HSP HSPA5

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Luminespib (VER-52296) is a potent HSP90 inhibitor with IC₅₀s of 7.8 and 21 nM for HSP90α and HSP90β, respectively^[1].

IC₅₀ & Target^[1]

HSP90α

7.8 nM (IC₅₀)

HSP90β

21 nM (IC₅₀)

GRP94

535 nM (IC₅₀)

TRAP-1

85 nM (IC₅₀)

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.001 μM Compound: NVP-AUY922	Antiproliferative activity against human A2780 cells after 72 hrs Antiproliferative activity against human A2780 cells after 72 hrs	[PMID: 24980703]
A549	GI₅₀	0.01 μM Compound: 1; AUY-922	Antiproliferative activity against human A549 cells measured after 48 hrs by SRB assay Antiproliferative activity against human A549 cells measured after 48 hrs by SRB assay	[PMID: 32683166]
A549	GI₅₀	0.026 μM Compound: NVP-AUY922	Growth inhibition of human A549 cells after 72 hrs by SRB assay Growth inhibition of human A549 cells after 72 hrs by SRB assay	[PMID: 25313505]
A549	IC₅₀	39 nM Compound: NVP-AUY922	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32352777]
A549	IC₅₀	60 nM Compound: AUY922	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 29698859]
BT-474	IC₅₀	0.01 μM Compound: NVP-AUY922	Induction of Her2 degradation in human BT474 cells assessed as inhibition of signal by immunocytochemistry Induction of Her2 degradation in human BT474 cells assessed as inhibition of signal by immunocytochemistry	[PMID: 24980703]
BT-474	IC₅₀	14 nM Compound: AUY922	Antiproliferative activity against human BT474 cells after 72 hrs by SRB assay Antiproliferative activity against human BT474 cells after 72 hrs by SRB assay	[PMID: 29698859]
CAPAN-1	IC₅₀	657 nM Compound: NVP-AUY922	Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human Capan1 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32352777]
DU-145	GI₅₀	0.005 μM Compound: 40f, VER-52296, NVP-AUY922	Growth inhibition of human DU145 cells by SRB assay Growth inhibition of human DU145 cells by SRB assay	[PMID: 18020435]
DU-145	IC₅₀	21 nM Compound: AUY922	Antiproliferative activity against human DU145 cells after 72 hrs by SRB assay Antiproliferative activity against human DU145 cells after 72 hrs by SRB assay	[PMID: 29698859]
EBC-1	IC₅₀	13 nM Compound: AUY922	Antiproliferative activity against human EBC1 cells after 72 hrs by SRB assay Antiproliferative activity against human EBC1 cells after 72 hrs by SRB assay	[PMID: 29698859]
Fibroblast	CC₅₀	0.008 μM Compound: 2, AUY-922	Cytotoxicity against Huntington's disease patient derived fibroblasts after 48 hrs by CellTiter Glo assay Cytotoxicity against Huntington's disease patient derived fibroblasts after 48 hrs by CellTiter Glo assay	[PMID: 24673104]
HCC827	IC₅₀	7 nM Compound: 7; NVP-AUY922	Cytotoxicity against gefitinib-resistant human HCC827 cells assessed as inhibition of cell proliferation by MTS assay Cytotoxicity against gefitinib-resistant human HCC827 cells assessed as inhibition of cell proliferation by MTS assay	[PMID: 26844689]
HCT-116	GI₅₀	0.016 μM Compound: 40f, VER-52296, NVP-AUY922	Growth inhibition of human HCT116 cells after 24 hrs by SRB assay Growth inhibition of human HCT116 cells after 24 hrs by SRB assay	[PMID: 18020435]
HCT-116	IC₅₀	121 nM Compound: NVP-AUY922	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32352777]
HCT-116	IC₅₀	16 nM Compound: AUY922	Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 29698859]
L02	IC₅₀	1364 nM Compound: NVP-AUY922	Cytotoxicity agains human HL7702 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxicity agains human HL7702 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32352777]
MDA-MB-231	IC₅₀	21 nM Compound: AUY922	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 29698859]
MIA PaCa-2	IC₅₀	38 nM Compound: NVP-AUY922	Antiproliferative activity against human MIAPaCa2 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human MIAPaCa2 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 32352777]
NCI-H1975	GI₅₀	0.02 μM Compound: 1; AUY-922	Antiproliferative activity against human NCI-H1975 cells measured after 48 hrs by SRB assay Antiproliferative activity against human NCI-H1975 cells measured after 48 hrs by SRB assay	[PMID: 32683166]
NCI-H3122	IC₅₀	0.014 μM Compound: 3; AUY922	Antiproliferative activity against human NCI-H3122 cells after 72 hrs by SRB assay Antiproliferative activity against human NCI-H3122 cells after 72 hrs by SRB assay	[PMID: 27688186]
NCI-H3122	IC₅₀	12.4 nM Compound: AUY922	Antiproliferative activity against human NCI-H3122 cells after 72 hrs by SRB assay Antiproliferative activity against human NCI-H3122 cells after 72 hrs by SRB assay	[PMID: 29698859]
NCI-H460	IC₅₀	0.0024 μM Compound: 5, NVP-AUY922	Cytotoxicity against human NCI-H460 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay Cytotoxicity against human NCI-H460 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 24565573]
NCI-H460	IC₅₀	0.0024 μM Compound: 10, VER-52296/NVP-AUY922	Cytotoxicity against human NCI-H460 after 72 hrs by sulforhodamine B assay Cytotoxicity against human NCI-H460 after 72 hrs by sulforhodamine B assay	[PMID: 22066525]
NCI-H460	GI₅₀	0.03 μM Compound: 1; AUY-922	Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by SRB assay Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by SRB assay	[PMID: 32683166]
NCI-H460	IC₅₀	2.4 nM Compound: NVP-AUY922	Cytotoxicity against human NCI-H460 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human NCI-H460 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 24588105]
NCI-H460	IC₅₀	23 nM Compound: AUY922	Antiproliferative activity against human NCI-H460 cells after 72 hrs by SRB assay Antiproliferative activity against human NCI-H460 cells after 72 hrs by SRB assay	[PMID: 29698859]
NCI-N87	IC₅₀	83 nM Compound: AUY922	Antiproliferative activity against human NCI-N87 cells after 72 hrs by SRB assay Antiproliferative activity against human NCI-N87 cells after 72 hrs by SRB assay	[PMID: 29698859]
PC-3M	GI₅₀	0.006 μM Compound: 40f, VER-52296, NVP-AUY922	Growth inhibition of human PC3M cells by SRB assay Growth inhibition of human PC3M cells by SRB assay	[PMID: 18020435]
SF-268	GI₅₀	0.006 μM Compound: 40f, VER-52296, NVP-AUY922	Growth inhibition of human SF268 cells by SRB assay Growth inhibition of human SF268 cells by SRB assay	[PMID: 18020435]
Sf9	IC₅₀	8 nM Compound: NVP-AUY922	Displacement of GM-BODIPY from human full length HSP90 alpha expressed in baculovirus-infected Sf9 cells after 16 hrs by fluorescence polarization assay Displacement of GM-BODIPY from human full length HSP90 alpha expressed in baculovirus-infected Sf9 cells after 16 hrs by fluorescence polarization assay	[PMID: 24751441]
SK-MEL-28	GI₅₀	0.005 μM Compound: 40f, VER-52296, NVP-AUY922	Growth inhibition of human SKMel28 cells by SRB assay Growth inhibition of human SKMel28 cells by SRB assay	[PMID: 18020435]
U-87MG ATCC	GI₅₀	0.008 μM Compound: 40f, VER-52296, NVP-AUY922	Growth inhibition of human U87MG cells by SRB assay Growth inhibition of human U87MG cells by SRB assay	[PMID: 18020435]
U-87MG ATCC	IC₅₀	31 nM Compound: AUY922	Antiproliferative activity against human U87MG cells after 72 hrs by SRB assay Antiproliferative activity against human U87MG cells after 72 hrs by SRB assay	[PMID: 29698859]

体外研究
(In Vitro)

Luminespib 是一种强效且选择性的 HSP90 抑制剂，对 HSP90β 的 IC₅₀s 值和 K_is 值分别为 21 ± 16、8.2 ± 0.7 nM，对 HSP90α 的 IC₅₀s 值和 K_is 值分别为 7.8 ± 1.8、9.0 ± 5.0 nM。Luminespib 对 GRP94 和 TRAP-1 表现出较弱的活性，IC₅₀s 值分别为 535 ± 51 nM（K_i，108 nM）和 85 ± 8 nM（K_i，53 nM）。 Luminespib 对各种人类肿瘤细胞系的增殖有抑制作用 (2.3-49.6 nM)，诱导细胞周期停滞和凋亡，并消耗人类癌细胞中的客户蛋白 (80 nM)^[1]。Luminespib (100 nM) 显著降低 CD40L 成纤维细胞诱导的免疫表型和 STAT3 信号传导变化，但对慢性淋巴细胞白血病 (CLL) 细胞的活力没有影响。Luminespib (500 nM) 与 NSC 118218 联合使用比单独使用任何一种药物更有效地诱导共培养细胞凋亡，并克服成纤维细胞对 Hsp90 抑制剂的耐药性^[2]。Luminespib 对胰腺癌细胞表现出很强的抑制作用，IC₅₀ 值为 10 nM。 Luminespib (10 nM) 可降低 EGFR 的表达和表皮生长因子 (EGF) 介导的激活，并通过降低 ERK^{Thr202/Tyr204} 的下游磷酸化来显著破坏 EGF 信号传导。Luminespib (10 nM) 可在没有和存在 EGF 的情况下显著阻止胰腺癌细胞的迁移和侵袭^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Luminespib（50、75 mg/kg，腹腔注射）显著抑制肿瘤生长速度，降低人类肿瘤异种移植模型中第 11 天肿瘤的平均重量^[2]。
Luminespib（50 mg/kg/周，3×25 mg/kg/周）显著降低 L3.6pl 胰腺癌细胞小鼠模型中的肿瘤生长速度并降低肿瘤重量^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

465.54

Formula

C₂₆H₃₁N₃O₅

CAS 号

747412-49-3

性状

固体

颜色

Light yellow to gray

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 62 mg/mL (133.18 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1480 mL	10.7402 mL	21.4804 mL
5 mM	0.4296 mL	2.1480 mL	4.2961 mL
10 mM	0.2148 mL	1.0740 mL	2.1480 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.37 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.37 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.37 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
方案四

请依序添加每种溶剂： 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 2.5 mg/mL (5.37 mM); 澄清溶液
方案五

请依序添加每种溶剂： 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.37 mM); 澄清溶液

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.81%

选择批次：

Data Sheet (659 KB) SDS (393 KB)

COA (296 KB) HNMR (199 KB) LCMS (120 KB) 元素分析报告 (219 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Eccles, Suzanne A., et al. NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis. Cancer Research (2008), 68(8), 2850-2860. [Content Brief]

[2]. Best OG, et al. Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with NSC 118218 against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype. Leuk Lymphoma. 2012 Jul 9. [Content Brief]

[3]. Moser C, et al. Stoeltzing O.Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. Anticancer Res. 2012 Jul;32(7):2551-61. [Content Brief]

Cell Assay ^[1]	Cell lines are grown in DMEM/10% FCS, 2 mM glutamine, and nonessential amino acids in a humidified atmosphere of 5% CO₂ in air. All lines are free of Mycoplasma. Cell proliferation is determined using the SRB assay for tumor cells and prostate epithelial cells, the WST-1 assay for MCF10A and HB119, or an alkaline phosphatase assay for HUVEC and HDMEC. GI₅₀ is the compound concentration inhibiting cell proliferation by 50% compared with vehicle controls. Active caspase-3/7 is measured using a homogenous caspase assay kit^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Mice^[1] For efficacy studies, human tumor xenografts are established s.c. in athymic mice. WM266.4 cells are also injected i.v. to generate experimental lung metastases and PC3LN3 prostate carcinoma cells are implanted into the prostates of male mice. Dosing by i.p. with Luminespib commences when tumors are well established. Tumor growth is monitored and at study end samples are harvested for analysis^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Eccles, Suzanne A., et al. NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis. Cancer Research (2008), 68(8), 2850-2860. [Content Brief] [2]. Best OG, et al. Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with NSC 118218 against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype. Leuk Lymphoma. 2012 Jul 9. [Content Brief] [3]. Moser C, et al. Stoeltzing O.Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer. Anticancer Res. 2012 Jul;32(7):2551-61. [Content Brief]

Luminespib 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.1480 mL	10.7402 mL	21.4804 mL	53.7011 mL
	5 mM	0.4296 mL	2.1480 mL	4.2961 mL	10.7402 mL
	10 mM	0.2148 mL	1.0740 mL	2.1480 mL	5.3701 mL
	15 mM	0.1432 mL	0.7160 mL	1.4320 mL	3.5801 mL
	20 mM	0.1074 mL	0.5370 mL	1.0740 mL	2.6851 mL
	25 mM	0.0859 mL	0.4296 mL	0.8592 mL	2.1480 mL
	30 mM	0.0716 mL	0.3580 mL	0.7160 mL	1.7900 mL
	40 mM	0.0537 mL	0.2685 mL	0.5370 mL	1.3425 mL
	50 mM	0.0430 mL	0.2148 mL	0.4296 mL	1.0740 mL
	60 mM	0.0358 mL	0.1790 mL	0.3580 mL	0.8950 mL
	80 mM	0.0269 mL	0.1343 mL	0.2685 mL	0.6713 mL
	100 mM	0.0215 mL	0.1074 mL	0.2148 mL	0.5370 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Luminespib747412-49-3VER-52296 AUY922 NVP-AUY922VER52296VER 52296AUY922AUY 922AUY-922HSPAutophagyApoptosisHeat shock proteinsInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Luminespib (Synonyms: VER-52296; AUY922; NVP-AUY922)

Customer Review

MCE 顾客使用本产品发表的 18 篇科研文献

Luminespib 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 HSP 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Luminespib 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Luminespib (Synonyms: VER-52296; AUY922; NVP-AUY922)

Customer Review

Luminespib 相关抗体

MCE 顾客使用本产品发表的 18 篇科研文献

Luminespib 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 HSP 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Luminespib 相关抗体:

摩尔计算器

稀释计算器

Luminespib 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z